Sign In
Buy VERA
$31.27
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
02:29pm, Tuesday, 26'th May 2026
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Commi
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
07:30am, Thursday, 07'th May 2026
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Pr
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
07:30am, Monday, 04'th May 2026
BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 10'th Apr 2026
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation C
JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA
05:03am, Tuesday, 07'th Apr 2026
JPMorgan Chase and Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) by 73.5% in the third quarter, according to the company in its most recent disclosure with the Securities an
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
07:35am, Wednesday, 01'st Apr 2026
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech lands
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 27'th Mar 2026
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
07:30am, Wednesday, 25'th Mar 2026
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients wi
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages
02:30am, Sunday, 22'nd Mar 2026
Shares of Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBea
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
01:49pm, Friday, 20'th Mar 2026
Integral Health bought 100,000 Vera Therapeutics shares for an estimated $3.55 million in the fourth quarter. Meanwhile, the quarter-end position value increased by $41.75 million, reflecting both sha
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
02:03pm, Monday, 16'th Mar 2026
Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end posi
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
10:36am, Friday, 13'th Mar 2026
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 millio
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 06'th Mar 2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation C
